Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ARS Pharmaceuticals (SPRY) Amortizatization of Intangibles: 2020-2024

Historic Amortizatization of Intangibles for ARS Pharmaceuticals (SPRY) over the last 5 years, with Dec 2024 value amounting to -$7.3 million.

  • ARS Pharmaceuticals' Amortizatization of Intangibles fell 40.20% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.2 million, marking a year-over-year decrease of 205.00%. This contributed to the annual value of -$7.3 million for FY2024, which is 5.93% down from last year.
  • According to the latest figures from FY2024, ARS Pharmaceuticals' Amortizatization of Intangibles is -$7.3 million, which was down 5.93% from -$6.8 million recorded in FY2023.
  • Over the past 5 years, ARS Pharmaceuticals' Amortizatization of Intangibles peaked at $1.1 million during FY2021, and registered a low of -$7.3 million during FY2024.
  • Over the past 3 years, ARS Pharmaceuticals' median Amortizatization of Intangibles value was -$6.8 million (recorded in 2023), while the average stood at -$4.6 million.
  • As far as peak fluctuations go, ARS Pharmaceuticals' Amortizatization of Intangibles rose by 6.80% in 2021, and later tumbled by 2,502.81% in 2023.
  • Over the past 5 years, ARS Pharmaceuticals' Amortizatization of Intangibles (Yearly) stood at $1.1 million in 2020, then grew by 6.80% to $1.1 million in 2021, then slumped by 75.13% to $285,000 in 2022, then slumped by 2,502.81% to -$6.8 million in 2023, then fell by 5.93% to -$7.3 million in 2024.